Skip to main content

Table 3 Demographics comparison of the elderly and younger patients after PS matching

From: Liver resection for colorectal liver-limited metastases in elderly patients: a propensity score matching analysis

Variable Aged < 70 years (n = 128) Aged ≥ 70 years (n = 64) P value Standardized mean difference
Age (years) 57 (31–69) 72.5 (70–83) < 0.001  
Gender, male 73 (57.0%) 43 (67.2%) 0.175 0.075
ASA    0.200 0.083
 I–II 106 (82.8%) 48 (75.0%)   
 III 22 (17.2%) 16 (25.0%)   
Comorbidity 65 (50.8%) 41 (61.1%) 0.081 0.086
 Cerebrovascular disease 4 (3.1%) 2 (3.1%) 1.000 < 0.001
 Arrhythmia 3 (2.3%) 1 (1.6%) 1.000 < 0.001
 Ischemic heart disease 11 (8.6%) 6 (9.4%) 0.857 0.076
 Diabetes mellitus 21 (16.4%) 12 (18.8%) 0.685 0.089
 Hypertension 49 (38.3%) 31 (48.4%) 0.178 0.077
 Chronic obstructive pulmonary disease 0 (0.0%) 1 (1.6%) 0.333 0.083
 Chronic renal dysfunction 0 (0.0%) 1 (1.6%) 0.333 0.065
 Accompanying liver disease 10 (7.8%) 2 (3.1%) 0.343 0.076
Primary tumor sideness    0.447  
 Right side 24 (18.8%) 15 (23.4%)   
 Left side 104 (81.3%) 49 (76.6%)   
Primary T    0.557  
 pT1-T2 8 (6.3%) 6 (9.4%)   
 pT3-T4 120 (93.8%) 58 (90.6%)   
Primary N    0.653 0.035
 pN0 36 (28.1%) 20 (31.3%)   
 pN1-2 92 (71.9%) 44 (68.8%)   
Number of liver metastases(LM)   0.433 0.056
 ≤ 3 106 (82.8%) 50 (78.1%)   
 > 3 22 (17.2%) 14 (21.9%)   
Distribution of LM    1.000  
 Unilobar 80 (62.5%) 40 (62.5%)   
 Bilobar 48 (37.5%) 24 (37.5%)   
Maximum diameter of LM    0.509  
 ≤ 5 cm 103(80.5%) 54(84.4%)   
 > 5 cm 25(19.5%) 10(15.6%)   
Temporal relationship    0.126  
 Synchronous 61 (47.7%) 38 (59.4%)   
 Metachronous 67 (52.3%) 26 (40.6%)   
Preoperative chemotherpy cycles   1.000 < 0.001
 ≤ 6 cycles 122 (95.3%) 61 (95.3%)   
 > 6 cycles 6 (4.7%) 3 (4.7%)   
Preoperative clinical risk score (CRS)   0.535 0.065
 0–2 76 (59.4%) 35 (54.7%)   
 3–5 52 (40.6%) 29 (45.3%)   
RAS/BRAF mutation 47 (36.9%) 22 (34.4%) 0.750 0.046
Preoperative CEA (ng/ml) 9.10 (0.93–794.50) 9.41 (1.23–224.80) 0.858 0.102
Preoperative CA199 (U/ml) 28.11 (0.00–28,385.00) 24.06 (0.00–1354.00) 0.360  
Repeat resection after recurrence 20 (15.6%) 8 (12.5%) 0.563 0.078
Postoperative chemotherapy 86 (67.2%) 38 (59.4%) 0.286 0.094
Preoperative chemotherapy regimes   0.063  
 Oxaliplatin-based 37 (28.9%) 29 (45.3%)   
 Irinotecan-based 8 (6.3%) 5 (7.8%)   
 5-Fu-based 1 (0.8%) 2 (3.1%)   
 Hepatic artery infusion 4 (3.1%) 1 (1.6%)   
Postoperative chemotherapy regimes   0.601  
 Oxaliplatin-based 50 (39.1%) 28 (43.8%)   
 Irinotecan-based 22 (17.2%) 6 (9.4%)   
 5-Fu-based 8 (6.3%) 3 (4.7%)   
 Hepatic artery infusion 1 (0.8%) 0 (0%)